A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

This study is open to adults with advanced germ cell tumours, endometrial cancer, or ovarian cancer whose previous treatments were not successful. People can join the study if they have no remaining treatment options or if standard therapy is not suitable. The purpose of this study is to test increasing doses of BI 3820768 to find a dose that people with these types of cancer can tolerate and that may make tumours shrink. BI 3820768 is a type of treatment that may help the immune system fight cancer. This is the first time BI 3820768 is being tested in humans. The study has 2 parts based on t

Trial Details

NCT ID
NCT07306559
Phase
PHASE1
Sponsor
Boehringer Ingelheim
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • BI 3820768
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Houston, Texas, United States|29.76328,-95.36327
  • Brussels, Belgium|50.85045,4.34878
  • Leuven, Belgium|50.87959,4.70093

Key Eligibility Criteria

  • Patient must be ≥18 years of age and at least at the legal age of consent in countries where it is older than 18 years at the time of signature on …
  • For patients with endometrial cancer (EC) and ovarian cancer (OVC), signed and dated written ICF1 for target testing.
  • Signed and dated ICF2 for all patients describing the study in accordance with International Council on Harmonisation Good Clinical Practice (ICH-G…
  • Prior to Screening Visit 02, confirmed target-positivity for EC and OVC based on central laboratory testing of tumour tissue sample.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →